Top news of the week: 13.10.2020.
Biotechnology, Medicine, Human respiratory syncytial virus, Heart failure, Lead time, Google
Startups
This will resonate w/ any team that’s been through this unique, cliffhanger, company-defining moment.The surreal camaraderie when you get the results: champagne popping or sinking feeling. Been through it a few times! @AMahadevia @LifeSciVC https://t.co/VZNzaGcZGR
OpenPlaying To Win: Scenario Planning For Binary Readouts In Biotech
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this fall, we prepared to report Phase III data for tebipenem HBr, our oral ...
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
Recent deals for MyoKardia and The Medicines Co. may be hard to follow, since venture investors and big pharma acquirers have largely ignored cardiovascular drugs.
The 6 life science real estate markets to watch as the red-hot biotech and pharmaceutical sector draws in billions of dollars in funding https://t.co/TqGHRPYYUH
OpenThe 6 life science real estate markets to watch as the red-hot biotech and pharmaceutical sector draws in billions of dollars in funding
With venture funding and NIH funding up in 2020, a CBRE report looked at some of the fastest-growing life science clusters in the country.
Chutes & Ladders—Sanofi CSO Nabel steps down in favor of insider Nestle https://t.co/o9Yk9FgLce https://t.co/lNRgadHCtv
OpenChutes & Ladders—Sanofi CSO Nabel steps down in favor of insider Nestle
Sanofi's CSO Nabel steps down from role; BioMarin adds Eggan to head early research; Shams joins ProQR as CSO.
Here's how 4 top law firms have been taking VC-style stakes in their own clients including Peloton and Snowflake — and why many of these lucrative bets fly under the radar https://t.co/VeXdO5rVI0
OpenHere's how 4 top law firms have been taking VC-style stakes in their own clients including Peloton and Snowflake — and why many of these lucrative bets fly under the radar
Lawyers at Cooley, Fenwick, Gunderson and Wilson Sonsini are all known to take stakes in some tech- and life sciences-industry clients.
RT @frankvinluan: In this week of Nobel Prize announcements, here's @xconomy's recap of the top #biotech & #pharma news headlines... https://t.co/eLKEmeDmmx
OpenBio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them
US backs AstraZeneca #COVID19 antibody drug with $486M in funding https://t.co/qBff8JDZ2a by @NedPagliarulo $AZN $REGN $LLY
OpenUS backs AstraZeneca COVID-19 antibody drug with $486M in funding
Days after President Donald Trump was treated with a similar antibody therapy from Regeneron, his administration is backing another candidate being tested by British drugmaker AstraZeneca.
"The biotech sector may be the single most attractive subsector within commercial real estate today."
https://t.co/nXRDdsXcjL
OpenCovid drives historic demand for life sciences real estate and these REITs, report says
Rents are rising for lab space, vacancies are plunging and research and development, and employment and new development are expanding further, thanks to strong venture capital investment.